Drugs / H7N9 live influenza vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02480101 Comparator | Oct → Dec 2014 | influenza | Research Institute of Influenza, Russia | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H7N9 live influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02480101 ↗ |
| Known as | A/17/Anhui/2013/61 (H7N9) Influenza Vaccine | “Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine” NCT02480101 ↗ |
| Modality | Vaccine | “H7N9 live attenuated influenza vaccine (LAIV) candidate” PMID 26673391 ↗ Dec 2015 |
| Route | Intranasal | “Two doses of vaccine or placebo were administered intranasally 28 days apart” PMID 26673391 ↗ Dec 2015 |